4.8 Review

Chronic obstructive pulmonary disease in non-smokers

期刊

LANCET
卷 374, 期 9691, 页码 733-743

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/S0140-6736(09)61303-9

关键词

-

资金

  1. AstraZeneca
  2. Boehringer Ingelheim
  3. Chiesi Farmaceutici
  4. GlaxoSmithKline
  5. Novartis
  6. Pfizer
  7. Teva
  8. Union Chimique Belge

向作者/读者索取更多资源

Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide. Tobacco smoking is established as a major risk factor, but emerging evidence suggests that other risk factors are important, especially in developing countries. An estimated 25-45% of patients with COPD have never smoked; the burden of non-smoking COPD is therefore much higher than previously believed. About 3 billion people, half the worldwide population, are exposed to smoke from biomass fuel compared with 1.01 billion people who smoke tobacco, which suggests that exposure to biomass smoke might be the biggest risk factor for COPD globally. We review the evidence for the association of COPD with biomass fuel, occupational exposure to dusts and gases, history of pulmonary tuberculosis, chronic asthma, respiratory-tract infections during childhood, outdoor air pollution, and poor socioeconomic status.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据